Skip to main content

Table 2 Risk factors of fungal infection present within 2 weeks (3 months for immunosuppressants) prior to study entry, or at diagnosis, among 268 ICI patients receiving antifungal therapy in the China-SCAN study

From: Initial therapeutic strategy of invasive candidiasis for intensive care unit patients: a retrospective analysis from the China-SCAN study

Variables Empirical
N = 142
Pre-emptive
N = 53
Targeted
N = 73
P-value
Immune compromised, n (%)
 Immunosuppressant therapya 5 (3.5) 3 (5.7) 5 (6.8) 0.535
 HIV infection 1 (0.7) 1 (1.9) - 0.476
 Neutropenia 3 (2.1) - - 0.260
Previous antibiotic therapy, n (%)b
 cephalosporins 38 (26.8) 9 (17.0) 12 (16.4) 0.138
 carbapenems 49 (34.5) 18 (34.0) 20 (27.4) 0.554
 pennicillins 62 (43.7) 21 (39.6) 30 (41.1) 0.858
 quinolones 17 (12.0) 8 (15.1) 9 (12.3) 0.839
 glycopeptides 26 (18.3) 10 (18.9) 12 (16.4) 0.925
Life-sustaining treatments ≥ 24 h
 Invasive mechanical ventilation 113 (79.6) 47 (88.7) 60 (82.2) 0.337
 vasopressor 47 (33.1) 12 (22.6) 19 (26.0) 0.286
 Renal replacement therapy 8 (5.6) 5 (9.4) 8 (11.0) 0.345
Catheterization, n (%)c
 central venous 113 (79.6) 45 (84.9) 66 (90.4) 0.122
 indwelling arterial 27 (19.6) 13 (25.0) 6 (8.5) 0.040
 drainage tube 52 (36.6) 26 (49.1) 23 (31.5) 0.124
 urethral 104 (73.8) 43 (81.1) 53 (73.6) 0.534
Gastrointestinal dysfunction, n (%)d 72 (50.7) 32 (60.4) 45 (61.6) 0.229
Total parenteral nutrition, n (%) 70 (49.3) 30 (56.6) 41 (56.2) 0.513
Surgery, n (%) 59 (41.5) 24 (45.3) 25 (34.7) 0.457
 Abdominal 33 (23.2) 20 (37.7) 18 (24.7) 0.114
  1. Continuous variables are expressed as the means ± SD or medians (IQR). All the other data are raw numbers (%)
  2. aVariables included steroid therapy, which defined as > 0.5 mg/(kg · day)−1 prednisone over 1 month (n = 7), cancer chemotherapy (n = 6), post-solid organ transplant immunosuppression (n = 1), allogeneic bone marrow transplantation or allogeneic haematopoietic stem cell transplantation (n = 1), and tumor necrosis factor therapy (n = 1) within 3 months prior to study entry
  3. bAll patients receiving systemic drug therapy for ≥ 3 days within 2 weeks prior to study entry
  4. cVariables included patients who required treatments were catheterized within 2 weeks of the first positive sample no matter the catheter was removed or not before diagnosis
  5. dVariables included hemorrhage, food intolerance, perforation, surgery, acalculouscholecystitis or intra-abdominal hypertension